Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$13.27M$13.27M−13.6% vs Q2 2021 Net Income-$16.30M-$16.30MN/M vs Q2 2021 EPS Diluted-$0.36-$0.36N/M vs Q2 2021 Operating Income-$12,762,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,239,000N/M Margins · derivedOperating margin-96.2%−53.7 pt vs Q2 2021
Net margin-122.9%−42.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 2, 2022 · 33 d after period end